OCT 27, 2016 09:00 AM PDT
Achieving Reproducibility: Don't Let Antibodies be a Variable in Your Experiment
SPONSORED BY: Cell Signaling Technology
10 30 4145

  • Scientific Marketing Project Manager, Cell Signaling Technology
      Dr. Couvillon attended Colby College in Waterville, Maine (USA) where he majored in Biology and Chemistry. Post-graduation, he became a research associate in the laboratories of Dr. Christopher L. Carpenter and Lewis Cantley at the Harvard Medical School where he was introduced to the fascinating world of signal transduction, lipid kinases and the role of Ras-like proteins in disease. Under the tutelage of Dr. John H. Exton at Vanderbilt University (Nashville, Tennessee), Dr. Couvillon received his Ph.D. in Molecular Physiology and Biophysics while studying the role of Rho-family proteins and their regulators in neuronal function. He then returned to Harvard and Beth-Israel Deaconess Medical Center where he rejoined the Cantley lab to continue his work on Rho-family GTPases and their role in immune cell development and function, neuronal plasticity and cardiac development. Dr. Couvillon joined Cell Signaling Technology in 2009 as a Development Scientist, developing and validating antibody products in the MAPK, lipid signaling and other pathways. He has also worked extensively in the proteomics space, developing novel antibody reagents against novel post-translational modification and reagents that detect specific substrate motifs for high-throughput proteomics analysis. Dr. Couvillon currently works as a Scientific Project Manager focused on initiatives promoting antibody reproducibility in research.

    DATE:  October 27, 2016
    TIME:  9:00am PT, 12:00pm ET

    The importance of antibodies as tools in scientific research studies cannot be understated, yet these reagents have increasingly come under fire for their lack of reproducibility. Part of the issue is that the antibody market is composed of hundreds of vendors and resellers with varying definitions for validation and consistency. Cell Signaling Technology (CST) believes that antibody suppliers should be held accountable for the products they provide, but that vendors alone cannot solve the reproducibility “crisis”. How antibodies are validated and used in the laboratory is a critical component to this process. Researchers need to be more attentive to following established protocols and leverage the expertise of the scientists who have developed and tested the product they are using. Journals need to be more active in enforcing existing policies regarding materials and methods or develop more clear-cut means to identify and describe the use of biological reagents in published research. During this webinar we will address the role vendors, researchers, and journals should play in minimizing irreproducibility. We will also outline CST’s antibody validation process, while highlighting steps all users should consider when selecting and using antibodies in their research.

    Learning Objectives
    • Understand the importance of antibody validation and what roles vendors, researchers, and journals play in minimizing irreproducibility.
    • Learn what steps to consider when selecting and using antibodies for research.

    Show Resources
    Loading Comments...